ARDT · Ardent Health Inc. Common Stock
View on chartInsiders & Stakes
| Martin Bonick President and CEO | ▲ Buy | Grant | 1,437,937 Shares held | 4/1/2026 | View profile |
| Stephen C. Petrovich EVP, GC and Secretary | ▼ Sell | Tax Withholding | 773,919 Shares held | 9/25/2026 | View profile |
| Alfred Lumsdaine Chief Financial Officer | ▼ Sell | Tax Withholding | 325,794 Shares held | 9/25/2026 | View profile |
| Dave Caspers Chief Stores Officer | ▲ Buy | Grant | 174,930 Shares held | 7/1/2026 | View profile |
| David Raynor Byers SVP & Chief Accounting Officer | ▼ Sell | Tax Withholding | 129,921 Shares held | 9/25/2026 | View profile |
| Ellen Havdala Director | ▲ Buy | Grant | 115,367 Shares held | 4/1/2026 | View profile |
| William M. Goodyear Director | ▲ Buy | Grant | 115,367 Shares held | 4/1/2026 | View profile |
| Peter C. B. Bynoe Director | ▲ Buy | Grant | 115,367 Shares held | 4/1/2026 | View profile |
| Robert Thomas Webb Director | ▲ Buy | Grant | 78,215 Shares held | 4/1/2026 | View profile |
| Ethan Chernin President of Health Services | ▲ Buy | Grant | 68,396 Shares held | 3/11/2026 | View profile |
| David Schultz See Remarks | ▲ Buy | Grant | 64,172 Shares held | 4/1/2025 | View profile |
| Edmondo Robinson Director | ▲ Buy | Grant | 58,215 Shares held | 4/1/2026 | View profile |
| Suzanne Campion Director | ▲ Buy | Grant | 58,215 Shares held | 4/1/2026 | View profile |
| Mark R. Sotir Director | ▲ Buy | Grant | 38,709 Shares held | 4/1/2026 | View profile |
| Rahul Sen Director | ▲ Buy | Grant | 38,709 Shares held | 4/1/2026 | View profile |
| Robert DeMichiei Director | ▲ Buy | Open Market | 35,564 Shares held | 6/5/2026 | View profile |
| Peter J. Bulgarelli Pres&CEO-LHS/EVP Office-Ventas | ▲ Buy | Grant | 14,231 Shares held | 4/1/2026 | View profile |
Transaction History
| Alfred Lumsdaine | ▼ Sell | Tax Withholding | 3,389 | $36K | 9/25/2026 |
| Stephen C. Petrovich | ▼ Sell | Tax Withholding | 788 | $8K | 9/25/2026 |
| David Raynor Byers | ▼ Sell | Tax Withholding | 524 | $6K | 9/25/2026 |
| Dave Caspers | ▲ Buy | Grant | 103,653 | $0 | 7/1/2026 |
| Robert DeMichiei | ▲ Buy | Open Market | 11,260 | $98K | 6/5/2026 |
| Alfred Lumsdaine | ▲ Buy | Open Market | 10,000 | $88K | 6/5/2026 |
| Peter J. Bulgarelli | ▲ Buy | Grant | 14,231 | $0 | 4/1/2026 |
| Ellen Havdala | ▲ Buy | Grant | 14,231 | $0 | 4/1/2026 |
| Mark R. Sotir | ▲ Buy | Grant | 14,231 | $0 | 4/1/2026 |
| Rahul Sen | ▲ Buy | Grant | 14,231 | $0 | 4/1/2026 |
| Robert Thomas Webb | ▲ Buy | Grant | 14,231 | $0 | 4/1/2026 |
| Edmondo Robinson | ▲ Buy | Grant | 14,231 | $0 | 4/1/2026 |
| Dave Caspers | ▼ Sell | Tax Withholding | 2,684 | $23K | 4/1/2026 |
| Dave Caspers | ▲ Buy | Grant | 35,673 | $0 | 4/1/2026 |
| Stephen C. Petrovich | ▼ Sell | Tax Withholding | 1,808 | $16K | 4/1/2026 |
| Stephen C. Petrovich | ▲ Buy | Grant | 24,904 | $0 | 4/1/2026 |
| David Raynor Byers | ▼ Sell | Tax Withholding | 924 | $8K | 4/1/2026 |
| David Raynor Byers | ▲ Buy | Grant | 11,538 | $0 | 4/1/2026 |
| Alfred Lumsdaine | ▼ Sell | Tax Withholding | 4,381 | $38K | 4/1/2026 |
| Alfred Lumsdaine | ▲ Buy | Grant | 53,846 | $0 | 4/1/2026 |
| Martin Bonick | ▼ Sell | Tax Withholding | 10,952 | $95K | 4/1/2026 |
| Martin Bonick | ▲ Buy | Grant | 134,615 | $0 | 4/1/2026 |
| Robert DeMichiei | ▲ Buy | Grant | 14,231 | $0 | 4/1/2026 |
| William M. Goodyear | ▲ Buy | Grant | 14,231 | $0 | 4/1/2026 |
| Suzanne Campion | ▲ Buy | Grant | 14,231 | $0 | 4/1/2026 |
| Peter C. B. Bynoe | ▲ Buy | Grant | 14,231 | $0 | 4/1/2026 |
| Stephen C. Petrovich | ▼ Sell | Tax Withholding | 1,425 | $12K | 3/31/2026 |
| David Raynor Byers | ▼ Sell | Tax Withholding | 819 | $7K | 3/31/2026 |
| Alfred Lumsdaine | ▼ Sell | Tax Withholding | 2,510 | $21K | 3/31/2026 |
| Martin Bonick | ▼ Sell | Tax Withholding | 8,026 | $69K | 3/31/2026 |
| Stephen C. Petrovich | ▲ Buy | Grant | 34,733 | $0 | 3/11/2026 |
| Alfred Lumsdaine | ▲ Buy | Grant | 61,081 | $0 | 3/11/2026 |
| Ethan Chernin | ▲ Buy | Grant | 32,408 | $0 | 3/11/2026 |
| Martin Bonick | ▲ Buy | Grant | 195,316 | $0 | 3/11/2026 |
| David Raynor Byers | ▲ Buy | Grant | 8,859 | $0 | 3/11/2026 |
| Alfred Lumsdaine | ▼ Sell | Tax Withholding | 3,389 | $45K | 9/25/2025 |
| Stephen C. Petrovich | ▼ Sell | Tax Withholding | 788 | $10K | 9/25/2025 |
| David Raynor Byers | ▼ Sell | Tax Withholding | 524 | $7K | 9/25/2025 |
| Robert DeMichiei | ▲ Buy | Grant | 10,073 | $0 | 4/2/2025 |
| David Raynor Byers | ▲ Buy | Grant | 11,565 | $0 | 4/1/2025 |
| Ethan Chernin | ▲ Buy | Grant | 20,914 | $0 | 4/1/2025 |
| David Schultz | ▲ Buy | Grant | 26,985 | $0 | 4/1/2025 |
| Stephen C. Petrovich | ▲ Buy | Grant | 22,263 | $0 | 4/1/2025 |
| Alfred Lumsdaine | ▲ Buy | Grant | 53,971 | $0 | 4/1/2025 |
| Martin Bonick | ▲ Buy | Grant | 134,927 | $0 | 4/1/2025 |
| Dave Caspers | ▲ Buy | Grant | 7,711 | $0 | 4/1/2025 |
| Dave Caspers | ▼ Sell | Tax Withholding | 2,480 | $32K | 4/1/2025 |
| Dave Caspers | ▲ Buy | Grant | 33,057 | $0 | 4/1/2025 |
| Ethan Chernin | ▼ Sell | Tax Withholding | 1,332 | $18K | 3/31/2025 |
| David Schultz | ▼ Sell | Tax Withholding | 1,825 | $25K | 3/31/2025 |
| Stephen C. Petrovich | ▼ Sell | Tax Withholding | 1,428 | $20K | 3/31/2025 |
| Alfred Lumsdaine | ▼ Sell | Tax Withholding | 2,510 | $35K | 3/31/2025 |
| Martin Bonick | ▼ Sell | Tax Withholding | 12,970 | $178K | 3/31/2025 |
| David Raynor Byers | ▼ Sell | Tax Withholding | 676 | $9K | 3/31/2025 |
| Suzanne Campion | ▲ Buy | Grant | 12,916 | $0 | 3/21/2025 |
| Peter C. B. Bynoe | ▲ Buy | Grant | 12,916 | $0 | 3/21/2025 |
| William M. Goodyear | ▲ Buy | Grant | 12,916 | $0 | 3/21/2025 |
| Ellen Havdala | ▲ Buy | Grant | 12,916 | $0 | 3/21/2025 |
| Rahul Sen | ▲ Buy | Grant | 12,916 | $0 | 3/21/2025 |
| Mark R. Sotir | ▲ Buy | Grant | 12,916 | $0 | 3/21/2025 |
| Edmondo Robinson | ▲ Buy | Grant | 12,916 | $0 | 3/21/2025 |
| Robert Thomas Webb | ▲ Buy | Grant | 12,916 | $0 | 3/21/2025 |
| William M. Goodyear | ▲ Buy | Grant | 10,793 | $0 | 12/12/2024 |
| Robert Thomas Webb | ▲ Buy | Grant | 10,793 | $0 | 12/12/2024 |
| Edmondo Robinson | ▲ Buy | Grant | 10,793 | $0 | 12/12/2024 |
| Ellen Havdala | ▲ Buy | Grant | 10,793 | $0 | 12/12/2024 |
| Peter C. B. Bynoe | ▲ Buy | Grant | 10,793 | $0 | 12/12/2024 |
| Suzanne Campion | ▲ Buy | Grant | 10,793 | $0 | 12/12/2024 |
| Robert Thomas Webb | ▲ Buy | Open Market | 10,000 | $175K | 11/8/2024 |
| Robert Thomas Webb | ▲ Buy | Open Market | 10,000 | $165K | 11/8/2024 |
| Stephen C. Petrovich | ▲ Buy | Grant | 9,699 | $0 | 9/25/2024 |
| Alfred Lumsdaine | ▲ Buy | Grant | 41,742 | $0 | 9/25/2024 |
| David Schultz | ▲ Buy | Grant | 16,535 | $0 | 9/25/2024 |
| David Raynor Byers | ▲ Buy | Grant | 6,447 | $0 | 9/25/2024 |
| Ellen Havdala | ▲ Buy | Grant | 11,562 | $0 | 7/18/2024 |
| William M. Goodyear | ▲ Buy | Grant | 11,562 | $0 | 7/18/2024 |
| Suzanne Campion | ▲ Buy | Grant | 11,562 | $0 | 7/18/2024 |
| Peter C. B. Bynoe | ▲ Buy | Grant | 11,562 | $0 | 7/18/2024 |
| David Schultz | ▲ Buy | Grant | 22,477 | $0 | 7/18/2024 |
| Alfred Lumsdaine | ▲ Buy | Grant | 30,922 | $0 | 7/18/2024 |
| Ethan Chernin | ▲ Buy | Grant | 16,406 | $0 | 7/18/2024 |
| David Raynor Byers | ▲ Buy | Grant | 8,329 | $0 | 7/18/2024 |
| Martin Bonick | ▲ Buy | Grant | 98,881 | $0 | 7/18/2024 |
| Stephen C. Petrovich | ▲ Buy | Grant | 17,584 | $0 | 7/18/2024 |
| Robert Thomas Webb | ▲ Buy | Grant | 11,562 | $0 | 7/18/2024 |
| Mark R. Sotir | ▲ Buy | Grant | 11,562 | $0 | 7/18/2024 |
| Rahul Sen | ▲ Buy | Grant | 11,562 | $0 | 7/18/2024 |
| Edmondo Robinson | ▲ Buy | Grant | 11,562 | $0 | 7/18/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
ARDT Schedules Q3 2026 Results Call and Webcast
Ardent Health announced the date for its third quarter 2026 earnings conference call and webcast. The call will provide management’s discussion of the latest financial results and operational updates. Investors often use such events to assess performance trends, especially as the stock currently shows strong momentum on the chart.
ARDT Schedules Q3 2026 Results Call and Webcast. Ardent Health announced the date for its third quarter 2026 earnings conference call and webcast. The call will provide management’s discussion of the latest financial results and operational updates. Investors often use such events to assess performance trends, especially as the stock currently shows strong momentum on the chart.